Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Van Der Torren, Cornelis R ^a,e   Verrijn Stuart, Annemarie A ^b   Lee, DaHae ^c,e   Meerding, Jenny ^b   Van De Velde, Ursule ^d,e   Pipeleers, Daniel ^d   Gillard, Pieter ^c,e   Keymeulen, Bart ^d,e   De Jager, Wilco ^b   Roep, Bart O ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d DIABETES RESEARCH CENTER   (Belgium)

^e Juvenile Diabetes Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALPHA INTERFERON; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CALGRANULIN C; CATHEPSIN L; CD14 ANTIGEN; CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; HEMOGLOBIN A1C; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 16; INTERLEUKIN 22; INTERLEUKIN 33; KIDNEY INJURY MOLECULE 1; LEPTIN; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SCATTER FACTOR; IMMUNOSUPPRESSIVE AGENT; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENGRAFTMENT; EXPLORATORY RESEARCH; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS ISLET TRANSPLANTATION; PROTEIN BLOOD LEVEL; BLOOD; CYTOLOGY; DIABETES MELLITUS, TYPE 1; METABOLISM; MIDDLE AGED; PANCREAS ISLET; TREATMENT OUTCOME;

ADIPOKINES; ADULT; BIOMARKERS; CHEMOKINES; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84954526590     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146649     Document Type: Article

References (49)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343(4):230-8. PMID: 10911004
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005; 54(7):2060-9. PMID: 15983207
3. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A. 2006; 103(46):17444-9. PMID: 17090674
4. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012; 35(7):1436-45. doi: 10.2337/dc12-0063 PMID: 22723582
5. Fiorina P, Venturini M, Folli F, Losio C, Maffi P, Placidi C, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005; 28 (6):1303-10. PMID: 15920043
6. Fiorina P, Gremizzi C, Maffi P, Caldara R, Tavano D, Monti L, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005; 28(6):1358-65. PMID: 15920052
7. Thompson DM, Begg IS, Harris C, Ao Z, Fung MA, Meloche RM, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation. 2008; 85(10):1400-5. doi: 10.1097/TP.0b013e318172ca07 PMID: 18497678
8. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008; 86(12):1762-6. doi: 10.1097/TP.0b013e318190b052 PMID: 19104418
9. Poggioli R, Faradji RN, Ponte G, Betancourt A, Messinger S, Baidal DA, et al. Quality of life after islet transplantation. Am J Transplant. 2006; 6(2):371-8. PMID: 16426323
10. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000; 105(2):125-33. PMID: 11095109
11. van de Linde P, Roep BO. T-cell assays to determine disease activity and clinical efficacy of immune therapy in type 1 diabetes. Am J Ther. 2005; 12(6):573-9. PMID: 16280651
12. Nanji SA, Shapiro AM. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs. 2004; 18(5):315-28. PMID: 15377174
13. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010; 59(4):947-57. doi: 10.2337/db09-0498 PMID: 20086230
14. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A. 2005; 102 (51):18425-30. PMID: 16339897
15. Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008; 3(6): e2435. doi: 10.1371/journal.pone.0002435 PMID: 18560516
16. Harlan DM, Kenyon NS, Korsgren O, Roep BO. Current advances and travails in islet transplantation. Diabetes. 2009; 58(10):2175-84. doi: 10.2337/db09-0476 PMID: 19794074
17. Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes. 1996; 45 (9):1147-56. PMID: 8772714
18. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999; 48 (3):484-90. PMID: 10078547
19. Velthuis JH, Unger WW, van der Slik AR, Duinkerken G, Engelse M, Schaapherder AF, et al. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia. 2009; 52(3):494-503. doi: 10.1007/s00125-008-1237-z PMID: 19104770
20. Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De Waele M, Mathieu C, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009; 58(10):2267-76. doi: 10.2337/db09-0160 PMID: 19602536
21. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant. 2009; 9(2):382-8. doi: 10.1111/j.1600-6143.2008.02479.x PMID: 19067657
22. Roelen DL, Huurman VA, Hilbrands R, Gillard P, Duinkerken G, van der Meer-Prins PW, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol. 2009; 156(1):141-8. doi: 10.1111/j.1365-2249.2008.03812.x PMID: 19161445
23. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013; 62(5):1656-64. doi: 10.2337/db12-1258 PMID: 23274902
24. Pfleger C, Schloot NC, Brendel MD, Burkart V, Hogenkamp V, Bretzel RG, et al. Circulating cytokines are associated with human islet graft function in type 1 diabetes. Clin Immunol. 2011; 138(2):154-61. doi: 10.1016/j.clim.2010.10.008 PMID: 21094094
25. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, et al. A multiplex immunoassay for human adipokine profiling. Clin Chem. 2010; 56(8):1320-8. doi: 10.1373/clinchem.2010.146118 PMID: 20530731
26. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009; 10:52. doi: 10.1186/1471-2172-10-52 PMID: 19785746
27. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods. 2005; 300(1-2):124-35. PMID: 15896801
28. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009; 5(4):219-26. doi: 10.1038/nrendo.2009.21 PMID: 19352320
29. Melzi R, Mercalli A, Sordi V, Cantarelli E, Nano R, Maffi P, et al. Role of CCL2/MCP-1 in islet transplantation. Cell Transplant. 2010; 19(8):1031-46. doi: 10.3727/096368910X514639 PMID: 20546673
30. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes. 2002; 51(1):55-65. PMID: 11756323
31. Festa A, D'Agostino R Jr., Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51(4):1131-7. PMID: 11916936
32. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003; 52(3):812-7. PMID: 12606524
33. Kiely A, McClenaghan NH, Flatt PR, Newsholme P. Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell line. J Endocrinol. 2007; 195(1):113-23. PMID: 17911403
34. Baeyens L, De Breuck S, Lardon J, Mfopou JK, Rooman I, Bouwens L. In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells. Diabetologia. 2005; 48(1):49-57. PMID: 15616797
35. Baeyens L, Bonne S, German MS, Ravassard P, Heimberg H, Bouwens L. Ngn3 expression during postnatal in vitro beta cell neogenesis induced by the JAK/STAT pathway. Cell Death Differ. 2006; 13 (11):1892-9. PMID: 16514419
36. Koblas T, Leontovyc I, Zacharovova K, Berkova Z, Kriz J, Girman P, et al. Activation of the Jak/Stat signalling pathway by leukaemia inhibitory factor stimulates trans-differentiation of human non-endocrine pancreatic cells into insulin-producing cells. Folia Biol (Praha). 2012; 58(3):98-105.
37. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009; 8(9):1444-50. PMID: 19342884
38. Dong H, Fahmy TM, Metcalfe SM, Morton SL, Dong X, Inverardi L, et al. Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. PLoS One. 2012; 7(12):e50265. doi: 10.1371/journal.pone.0050265 PMID: 23227162
39. Conway BR, Manoharan D, Manoharan D, Jenks S, Dear JW, McLachlan S, et al. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int. 2012; 82(7):812-8. doi: 10.1038/ki.2012.218 PMID: 22718188
40. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010; 27(10):1144-50. doi: 10.1111/j. 1464-5491.2010.03083.x PMID: 20854382
41. Jin ZK, Tian PX, Wang XZ, Xue WJ, Ding XM, Zheng J, et al. Kidney injury molecule-1 and osteopontin: new markers for prediction of early kidney transplant rejection. Mol Immunol. 2013; 54(3-4):457-64. doi: 10.1016/j.molimm.2013.01.013 PMID: 23435265
42. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011; 8(1):22.
43. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol. 2011; 41(11):3351-60. doi: 10.1002/eji. 201141629 PMID: 21887788
44. Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One. 2012; 7(10):e47830. doi: 10.1371/journal.pone.0047830 PMID: 23112853
45. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6(11):1123-32. PMID: 16200070
46. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007; 19 (3):281-6. PMID: 17433650
47. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med. 2010; 207(6):1293-305. doi: 10.1084/jem.20092054 PMID: 20498020
48. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al. IL-17 immunity in human type 1 diabetes. J Immunol. 2010; 185(3):1959-67. doi: 10.4049/jimmunol.1000788 PMID: 20592279
49. Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest. 2012; 122(10):3647-51. doi: 10.1172/JCI63089 PMID: 22996693